| scholarly article | Q13442814 |
| P2093 | author name string | Alter MJ | |
| Armstrong GL | |||
| Kuhnert WL | |||
| McQuillan GM | |||
| Simard EP | |||
| Wasley A | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | United States of America | Q30 |
| Hepatitis C virus | Q708693 | ||
| virus | Q808 | ||
| hepatitis C | Q154869 | ||
| P304 | page(s) | 705-14 | |
| P577 | publication date | 2006-05-16 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | |
| P478 | volume | 144 |
| Q35127108 | "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign. |
| Q42261507 | "To share or not to share?" Serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants. |
| Q39636766 | 17β-estradiol inhibits the production of infectious particles of hepatitis C virus |
| Q94570297 | A Big Step Forward in Hepatitis C Screening |
| Q37229672 | A Canadian screening program for hepatitis C: is now the time? |
| Q36776376 | A Large Outbreak of Hepatitis C Virus Infections in a Hemodialysis Clinic. |
| Q40888934 | A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. |
| Q50146065 | A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection |
| Q38755741 | A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment |
| Q31137825 | A biological substrate for somatoform disorders: importance of pathophysiology. |
| Q38906671 | A case study of a real-time evaluation of the risk of disease transmission associated with a failure to follow recommended sterilization procedures |
| Q28299722 | A comparative review of HLA associations with hepatitis B and C viral infections across global populations |
| Q53572231 | A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. |
| Q37035655 | A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans |
| Q39002495 | A functional role for NS5ATP9 in the induction of HCV NS5A-mediated autophagy |
| Q45174119 | A great time to invest in baby Boomer's hepatitis C! |
| Q35584505 | A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma |
| Q42254214 | A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. |
| Q42988684 | A nationwide seroepidemiology of hepatitis C virus infection in South Korea |
| Q21296858 | A new insight into hepatitis C vaccine development |
| Q34474056 | A novel multiplex real-time PCR assay for the concurrent detection of hepatitis A, B and C viruses in patients with acute hepatitis. |
| Q27023355 | A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection |
| Q60920135 | A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C |
| Q33394104 | A review of the treatment of chronic hepatitis C virus infection in cirrhosis |
| Q37067537 | A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors. |
| Q39047531 | A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care |
| Q52306466 | A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. |
| Q35106267 | Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people |
| Q35241062 | Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study |
| Q38064495 | Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. |
| Q33647262 | Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial |
| Q35997794 | Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease |
| Q54663186 | Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. |
| Q37162708 | Acute hepatitis C: a systematic review |
| Q43212676 | Acute hepatitis C: prospects and challenges |
| Q35021515 | Admixture analysis of spontaneous hepatitis C virus clearance in individuals of African descent |
| Q58697778 | Advanced Hepatocellular Carcinoma Tumor Stage at Diagnosis in the 1945-1965 Birth Cohort Reflects Poor Use of Hepatocellular Carcinoma Screening |
| Q51817130 | Advancing the Public's Health by Scaling Innovations in Clinical Quality. |
| Q37473956 | Alcohol Consumption Decisions among Nonabusing Drinkers Diagnosed with Hepatitis C: An Exploratory Sequential Mixed Methods Study |
| Q44926498 | Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis |
| Q64244143 | Alcohol and hepatocellular carcinoma |
| Q93140521 | Alcohol consumption as a cofactor for other liver diseases |
| Q40642769 | Alcohol intake alters immune responses and promotes CNS viral persistence in mice |
| Q39219152 | Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents |
| Q28070280 | Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections |
| Q34686844 | Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. |
| Q28084063 | Alcoholic hepatitis and HCV interactions in the modulation of liver disease |
| Q26773274 | Alcoholic liver disease and hepatitis C virus infection |
| Q90092754 | Aldehyde Dehydrogenase, Liver Disease and Cancer |
| Q35974996 | All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population |
| Q42251203 | All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses |
| Q36590778 | An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection |
| Q93192139 | An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015 |
| Q36651500 | An integrated alcohol abuse and medical treatment model for patients with hepatitis C |
| Q36090175 | An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential |
| Q35177951 | An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. |
| Q22065064 | An overview of elastography - an emerging branch of medical imaging. |
| Q35866961 | Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient |
| Q28481489 | Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response |
| Q30534669 | Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels |
| Q30746254 | Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer |
| Q45394018 | Anti-hepatitis C virus-positive blood donors: are women any different? |
| Q36478531 | Anti-rods and rings autoantibodies can occur in the hepatitis c-naïve population |
| Q37749115 | Antiviral therapy for hepatitis C: why are so few patients being treated? |
| Q47570370 | Antiviral treatment of HCV-related cirrhosis |
| Q51131252 | Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. |
| Q40820987 | Apportioning blame in the North American hepatitis C virus epidemic |
| Q45353791 | Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. |
| Q55041475 | Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. |
| Q87406414 | Assessment of hepatitis C risk factors and infection prevalence in a jail population |
| Q33643082 | Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence |
| Q40715941 | Association Between Hepatitis C Virus and Head and Neck Cancers |
| Q42251563 | Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection |
| Q34238510 | Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study |
| Q27490429 | Association of Hepatitis C Virus Seropositivity With Inflammatory Markers and Heart Failure in Persons With Coronary Heart Disease: Data From the Heart and Soul Study |
| Q36840571 | Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS). |
| Q43751876 | Association of tattooing and hepatitis C virus infection: a multicenter case-control study. |
| Q33712331 | Associations among behavior-related susceptibility factors in porphyria cutanea tarda |
| Q34124888 | Associations between serum lipids and hepatitis C antiviral treatment efficacy |
| Q27488759 | Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection |
| Q38826295 | Associations of place characteristics with HIV and HCV risk behaviors among racial/ethnic groups of people who inject drugs in the United States |
| Q37029796 | Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. |
| Q40078485 | Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection |
| Q40151088 | Audio-computer-assisted survey interview and patient navigation to increase chronic viral hepatitis diagnosis and linkage to care in urban health clinics. |
| Q33424591 | Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature |
| Q64126910 | Awareness of HCV infection among persons who inject drugs in San Diego, California |
| Q34077806 | Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City. |
| Q36102882 | Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV. |
| Q36416942 | Awareness of hepatitis C infection among women with and at risk for HIV. |
| Q36100389 | Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 |
| Q35008495 | Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States |
| Q36393781 | Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis |
| Q26775733 | Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection |
| Q27693824 | Best strategies for global HCV eradication |
| Q34725990 | Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. |
| Q33756904 | Biopsychosocial factors associated with pain in veterans with the hepatitis C virus |
| Q42270225 | Birth cohort testing for hepatitis C virus: implications for clinical social workers in health care settings |
| Q38066185 | Boceprevir and personalized medicine in hepatitis C virus infection |
| Q42232710 | Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score |
| Q34690368 | Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study |
| Q37990840 | Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. |
| Q38066441 | Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection |
| Q36702302 | Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C |
| Q33565080 | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
| Q57478112 | Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018 |
| Q30234676 | Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review |
| Q35998417 | Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? |
| Q40466919 | Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies? |
| Q26261171 | Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions |
| Q43856455 | Cancer-related risk factors and preventive measures in US Hispanics/Latinos |
| Q64892384 | Características demográficas actuales del virus de la hepatitis C. |
| Q56893596 | Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration |
| Q45806761 | Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? |
| Q42267181 | Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. |
| Q37301305 | Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus |
| Q43000669 | Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids |
| Q35785037 | Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy |
| Q92689530 | Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study |
| Q34072683 | Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. |
| Q38403350 | Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation |
| Q46459012 | Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination |
| Q27011203 | Changing the face of hepatitis C management - the design and development of sofosbuvir |
| Q46370317 | Changing trends in hepatitis C-related mortality in the United States, 1995-2004. |
| Q35258162 | Changing trends in viral hepatitis-associated hospitalizations in the American Indian/Alaska Native population, 1995-2007 |
| Q41118833 | Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans |
| Q40139704 | Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA. |
| Q28551538 | Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175 |
| Q28534370 | Chimeric mouse model for the infection of hepatitis B and C viruses |
| Q39846767 | Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. |
| Q36418455 | Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? |
| Q44019710 | Chronic hepatitis C as a risk factor for colorectal adenoma |
| Q41542344 | Chronic hepatitis C infection as a risk factor for renal cell carcinoma. |
| Q27490215 | Chronic hepatitis C is a common associated with hepatic granulomas |
| Q37148328 | Chronic hepatitis C virus (HCV) disease burden and cost in the United States |
| Q35501675 | Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users |
| Q36035889 | Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 |
| Q33799309 | Chronic liver disease mortality among male prison inmates in Texas, 1989-2003. |
| Q36409606 | Chronic pain treatment and health service utilization of veterans with hepatitis C virus infection |
| Q36595579 | Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment |
| Q34407096 | Clinical Case Registries: simultaneous local and national disease registries for population quality management |
| Q36650557 | Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. |
| Q34873114 | Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy |
| Q42286989 | Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study |
| Q42262211 | Clinical characteristics, treatment patterns and survival outcome of hepatocellular carcinoma patients aged 70 years or older: a single-center retrospective study from China |
| Q34022769 | Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients |
| Q34577157 | Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients |
| Q36112998 | Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California |
| Q48924876 | Clinical significance of perihepatic lymphadenopathy in patients with chronic hepatitis C infection |
| Q44930765 | Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis |
| Q56395991 | Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C |
| Q37442751 | Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence |
| Q42401021 | Communicating about alcohol consumption to nonharmful drinkers with Hepatitis C: patient and provider perspectives |
| Q36608121 | Communicating about alcohol consumption to nonharmful drinkers with hepatitis C: patient and provider perspectives. |
| Q92373959 | Community screening for hepatitis C virus infection in a low-prevalence population |
| Q35089934 | Community-based HCV screening: knowledge and attitudes in a high risk urban population |
| Q39690146 | Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. |
| Q34160592 | Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C |
| Q33411348 | Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort |
| Q92480921 | Comparing drug safety of hepatitis C therapies using post-market data |
| Q33631170 | Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens |
| Q56918825 | Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy |
| Q42198665 | Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. |
| Q35915031 | Comparison of hepatitis C virus treatment between incarcerated and community patients |
| Q35543361 | Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system |
| Q35139864 | Comparison of serial Hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation |
| Q36415087 | Compliance of healthcare professionals with safety measures for control of hepatitis viruses in hemodialysis centers: an experience from southeast iran |
| Q23912766 | Compliance with bloodborne pathogen standards at eight correctional facilities |
| Q36421892 | Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program |
| Q34770140 | Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma |
| Q42977416 | Confirmatory testing of hepatitis C virus-positive enzyme immunoassay results in limited-resource countries: should it be attempted? |
| Q38745903 | Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population |
| Q51847014 | Confronting the emerging epidemic of HCV infection among young injection drug users. |
| Q27490885 | Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients |
| Q28546457 | Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009 |
| Q34533951 | Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains |
| Q33831652 | Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals |
| Q34098870 | Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients |
| Q28483820 | Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users |
| Q40637339 | Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States |
| Q28488762 | Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States |
| Q35619161 | Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States |
| Q36115516 | Cost-effectiveness and population outcomes of general population screening for hepatitis C. |
| Q28540562 | Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C |
| Q44257436 | Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. |
| Q44310198 | Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial |
| Q41130579 | Cost-effectiveness of strategies for testing current hepatitis C virus infection |
| Q36799786 | Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness |
| Q34310417 | Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response |
| Q39266916 | County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States |
| Q37142229 | Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients |
| Q90694549 | Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West |
| Q34737843 | Current and future disease progression of the chronic HCV population in the United States |
| Q37884087 | Current drug discovery strategies for treatment of hepatitis C virus infection |
| Q38120201 | Current progress in development of hepatitis C virus vaccines. |
| Q37823576 | Current therapies for chronic hepatitis C. |
| Q35385005 | Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories |
| Q37968485 | Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents |
| Q38040256 | Cyclophilin involvement in the replication of hepatitis C virus and other viruses. |
| Q38216586 | Daclatasvir for the treatment of hepatitis C virus infection. |
| Q42202640 | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study |
| Q27012741 | Daclatasvir: potential role in hepatitis C |
| Q42386154 | Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. |
| Q42237379 | Deaths among people with hepatitis C in New York City, 2000-2011. |
| Q36192394 | Demographic characteristics and intravenous drug use among hepatitis C patients in the Kota Setar district, Kedah, Malaysia |
| Q36064140 | Demographic, risk, and spatial factors associated with over-the-counter syringe purchase among injection drug users |
| Q64922831 | Demographics of hepatitis C virus today. |
| Q35654548 | Demographics, socio-behavioral factors, and drug use patterns: what matters in spontaneous HCV clearance? |
| Q42279668 | Detection of hepatitis C virus transmission by use of DNA mass spectrometry |
| Q36523107 | Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection |
| Q87870147 | Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study |
| Q39063265 | Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus |
| Q38071682 | Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument |
| Q36756949 | Development of a Measure of Hepatitis C-alcohol Knowledge |
| Q36446336 | Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication |
| Q45971639 | Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. |
| Q79919466 | Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations |
| Q37580033 | Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis |
| Q42102990 | Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q38089735 | Diagnostic markers for hepatitis virus infection |
| Q39300667 | Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy |
| Q36875826 | Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients |
| Q36060366 | Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection |
| Q34295961 | Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. |
| Q35944189 | Differences in substance-related risk behavior between dual and triple diagnosed severely mentally ill adults |
| Q90694956 | Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma |
| Q38548066 | Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. |
| Q39780729 | Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. |
| Q38204468 | Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". |
| Q38714640 | Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor |
| Q34422414 | Disparities in Liver Cancer Incidence by Nativity, Acculturation, and Socioeconomic Status in California Hispanics and Asians |
| Q38873592 | Disparities in hepatitis C testing in U.S. veterans born 1945-1965. |
| Q43036298 | Does a little bit really go a long way? Infection prevention in ambulatory healthcare facilities |
| Q36792636 | Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features |
| Q33277431 | Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services |
| Q38630475 | Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. |
| Q43041150 | Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders |
| Q43047944 | Economic model of a birth cohort screening program for hepatitis C virus |
| Q37604532 | Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye? |
| Q35087836 | Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. |
| Q34078331 | Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir |
| Q42276687 | Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy |
| Q34923455 | Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers |
| Q37196683 | Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users |
| Q59654196 | Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting |
| Q39913723 | Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients |
| Q90435958 | Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review |
| Q39808598 | Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals |
| Q53516509 | Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. |
| Q27488980 | Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients |
| Q50567817 | Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. |
| Q43041036 | Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment |
| Q42205155 | Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial |
| Q34773912 | Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states |
| Q92862617 | Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system |
| Q33406379 | Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist |
| Q37220279 | Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama |
| Q91408013 | Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry |
| Q30234425 | Emerging concepts in alcoholic hepatitis |
| Q37031704 | Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma |
| Q37772514 | Emerging therapies for hepatitis C virus |
| Q80407707 | Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells |
| Q50559643 | Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. |
| Q37244221 | Enhanced chronic hepatitis C surveillance in New York City, April 2009-January 2011 |
| Q35549930 | Enhancing Drug Treatment Program Staff's Self-Efficacy to Support Patients' HCV Needs |
| Q28085718 | Enhancing our understanding of current therapies for hepatitis C virus (HCV) |
| Q58118311 | Epidemiology and Management of Hepatocellular Carcinoma |
| Q38118578 | Epidemiology and natural history of HCV infection. |
| Q33948292 | Epidemiology and natural history of hepatitis C virus infection |
| Q39867681 | Epidemiology and outcomes of hepatitis C infection in elderly US Veterans |
| Q51846147 | Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. |
| Q26753183 | Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence |
| Q22305500 | Epidemiology of hepatitis C virus infection |
| Q37391674 | Epidemiology of the viral hepatitis-HIV syndemic in San Francisco: a collaborative surveillance approach |
| Q36897895 | Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases |
| Q54945179 | Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. |
| Q86945740 | Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems |
| Q51852529 | Estimating acute viral hepatitis infections from nationally reported cases. |
| Q39965299 | Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. |
| Q28538968 | Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections |
| Q30622845 | Estimating the prevalence of hepatitis C infection in New York City using surveillance data |
| Q35147007 | Estimating the true prevalence of hepatitis C in rhode island |
| Q36149832 | Ethanol and hepatitis C virus suppress peptide-MHC class I presentation in hepatocytes by altering proteasome function |
| Q80463938 | Ethnic differences in hepatocellular carcinoma: implications for liver transplantation |
| Q40098372 | Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response. |
| Q36970296 | Ethnic variations in chronic liver diseases |
| Q36059493 | Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. |
| Q36896324 | Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center. |
| Q45364058 | Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus |
| Q38020157 | Evolving epidemiology of hepatitis C virus in the United States |
| Q40015818 | Examining hepatitis C virus testing practices in primary care clinics |
| Q38793145 | Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry |
| Q94022797 | Experiences of Oxford House Residents Living with the Hepatitis C Virus |
| Q61802124 | Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes |
| Q42282808 | Explaining differences in hepatitis C between U.S. veterans and nonveterans in treatment for substance abuse: results from a regression decomposition |
| Q43001479 | Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver |
| Q42995140 | Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver |
| Q36290295 | Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 |
| Q27490928 | Factors Associated with Prevalent Hepatitis C Infection Among HIV-Infected Women with No Reported History of Injection Drug Use: The Women's Interagency HIV Study (WIHS) |
| Q50550592 | Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. |
| Q36384812 | Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women |
| Q33777504 | Factors contributing to health disparities in liver transplantation in a Hispanic population |
| Q40076192 | Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virus-Infected Women. |
| Q30395238 | Familismo: influence on Hispanic health behaviors |
| Q34686484 | FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy |
| Q33834953 | Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. |
| Q34435133 | Formal Patient Education Improves Patient Knowledge of Hepatitis C in Vulnerable Populations |
| Q36955116 | Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response |
| Q54962720 | Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. |
| Q37825957 | Future hepatitis C virus treatment: interferon-sparing combinations |
| Q30235178 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C |
| Q81717578 | Future trends in hepatology: challenges and opportunities |
| Q42992649 | GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study |
| Q47101713 | GHOST: global hepatitis outbreak and surveillance technology. |
| Q37013260 | Ganetespib radiosensitization for liver cancer therapy |
| Q47573260 | Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy |
| Q35562840 | Gender differences in planning ability and hepatitis C virus among people who inject drugs. |
| Q46902016 | Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). |
| Q36373495 | Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C) |
| Q60922369 | Genetic and structural insights into broad neutralization of hepatitis C virus by human V1-69 antibodies |
| Q27487540 | Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans |
| Q38820559 | Genotype 1 hepatitis C virus and the pharmacist's role in treatment. |
| Q43034655 | Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia |
| Q57879539 | Geographic Variation in Organ Availability Is Responsible for Disparities in Liver Transplantation between Hispanics and Caucasians |
| Q34779752 | Geographic differences in the epidemiological features of HCV infection in Korea |
| Q35751678 | Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission |
| Q42981508 | Global burden of hepatitis C: considerations for healthcare providers in the United States |
| Q37077112 | Global control of hepatitis C: where challenge meets opportunity |
| Q29616009 | Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence |
| Q28706340 | Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide |
| Q35259824 | HBV and HCV therapy. |
| Q90115216 | HBsAg, Anti-HCV and Anti-HIV Seroprevalance Among Drug Users: a Retrospective Assessment |
| Q27487927 | HCV E2 protein binds directly to thyroid cells and induces IL-8 production: A new mechanism for HCV induced thyroid autoimmunity |
| Q38707521 | HCV Prevalence in Asian Americans in California |
| Q40161073 | HCV and HBV testing acceptability and knowledge among urban emergency department patients and pharmacy clients |
| Q36399139 | HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. |
| Q42987020 | HCV genotypes in Sicily: is there any evidence of a shift? |
| Q36837175 | HCV in incarcerated populations: an analysis of gender and criminality on risk |
| Q36882069 | HCV infection prevalence lower than expected among 18-40-year-old injection drug users in San Diego, CA. |
| Q33802968 | HCV-related mortality among male prison inmates in Texas, 1994-2003. |
| Q42196370 | HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics |
| Q36104175 | Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan |
| Q42992698 | Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study |
| Q36015711 | Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis |
| Q35538156 | Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. |
| Q98771721 | Hepatic Stellate Cells and Hepatocarcinogenesis |
| Q33559091 | Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. |
| Q36880485 | Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation. |
| Q37102265 | Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature |
| Q36532400 | Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse |
| Q45359330 | Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation |
| Q37627088 | Hepatitis B and C in African Americans: current status and continued challenges |
| Q43419544 | Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence |
| Q35737654 | Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States |
| Q29036593 | Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions |
| Q42623932 | Hepatitis B--more treatments, more testing, not enough data |
| Q49909667 | Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort |
| Q40528873 | Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals |
| Q55310381 | Hepatitis C Infection Patterns at a Tertiary Care Center in New York: A Cross-Sectional Study. |
| Q38501726 | Hepatitis C Infection in the Elderly |
| Q59357438 | Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers |
| Q33595820 | Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States |
| Q59357435 | Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert |
| Q89722139 | Hepatitis C Testing Among Perinatally Exposed Infants |
| Q59350307 | Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016 |
| Q38961563 | Hepatitis C Treatment and Barriers to Eradication |
| Q90302778 | Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors |
| Q27486013 | Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy |
| Q40258611 | Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. |
| Q26768490 | Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis |
| Q27485023 | Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes |
| Q27478218 | Hepatitis C Virus Infection in Guinea-Bissau: A Sexually Transmitted Genotype 2 with Parenteral Amplification? |
| Q45325560 | Hepatitis C Virus Infection in the Older Patient |
| Q90095540 | Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016 |
| Q55241575 | Hepatitis C Virus Screening Among Children Exposed During Pregnancy. |
| Q55397427 | Hepatitis C Virus Screening: A Review of the OraQuick Hepatitis C Virus Rapid Antibody Test. |
| Q35961748 | Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders |
| Q41931443 | Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials |
| Q33576161 | Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment |
| Q26801828 | Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? |
| Q90009625 | Hepatitis C Virus and Hispanic Criminal Justice Clients: A Missed Opportunity |
| Q37206722 | Hepatitis C among clients of health care for the homeless primary care clinics |
| Q37432092 | Hepatitis C and diabetes: the inevitable coincidence? |
| Q26799924 | Hepatitis C cirrhosis: New perspectives for diagnosis and treatment |
| Q22305417 | Hepatitis C genotype 6: A concise review and response-guided therapy proposal |
| Q41758808 | Hepatitis C in African Americans |
| Q42992102 | Hepatitis C in the United States |
| Q34178971 | Hepatitis C in the elderly: epidemiology, natural history, and treatment |
| Q34093840 | Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation |
| Q34263660 | Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis |
| Q46343410 | Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis |
| Q34090853 | Hepatitis C management by addiction medicine physicians: results from a national survey |
| Q37506029 | Hepatitis C performance measure on hepatitis A and B vaccination: missed opportunities? |
| Q34207872 | Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. |
| Q28083429 | Hepatitis C screening |
| Q39351107 | Hepatitis C screening beyond CDC guidelines in an Egyptian immigrant community |
| Q37722406 | Hepatitis C screening trends in a large integrated health system |
| Q36575211 | Hepatitis C screening: getting it right |
| Q37525298 | Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. |
| Q35543351 | Hepatitis C surveillance among youth and young adults in New York City, 2009-2013. |
| Q36758587 | Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services |
| Q34344995 | Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. |
| Q64128181 | Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010 |
| Q92728331 | Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance |
| Q35093134 | Hepatitis C treatment completion rates in routine clinical care |
| Q35783876 | Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens |
| Q92669682 | Hepatitis C viral infection in children |
| Q92669690 | Hepatitis C viral infection in incarcerated patients |
| Q92669753 | Hepatitis C viral infection in patients with chronic kidney disease |
| Q36607811 | Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. |
| Q37344238 | Hepatitis C virus (HCV): a review of immunological aspects |
| Q45398763 | Hepatitis C virus E2 envelope protein induces dendritic cell maturation |
| Q37460281 | Hepatitis C virus NS5A protein modulates IRF-7-mediated interferon-α signaling |
| Q27485064 | Hepatitis C virus RNA: Dinucleotide frequencies and cleavage by RNase L |
| Q41572035 | Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study |
| Q34990715 | Hepatitis C virus antibody prevalence, demographics and associated factors among persons screened at Hawai'i community-based health settings, 2010-2013. |
| Q42068631 | Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees |
| Q37358615 | Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care |
| Q27024231 | Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication |
| Q35139900 | Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States |
| Q36482820 | Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America |
| Q37237054 | Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes |
| Q37390189 | Hepatitis C virus in pregnancy |
| Q45382472 | Hepatitis C virus incident cases open the possibility to study transmission route and source of infection |
| Q45365333 | Hepatitis C virus infection among adolescents and young adults-Massachusetts, 2002-2009. |
| Q39854829 | Hepatitis C virus infection among children in aboriginal areas in Taiwan. |
| Q43174497 | Hepatitis C virus infection and health-related quality of life |
| Q35090649 | Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up |
| Q36179898 | Hepatitis C virus infection and nonalcoholic steatohepatitis |
| Q36447876 | Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients |
| Q34169767 | Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment? |
| Q34190570 | Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes |
| Q37899936 | Hepatitis C virus infection in USA: an estimate of true prevalence |
| Q34137925 | Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults |
| Q34980383 | Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan |
| Q26782033 | Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals |
| Q34101320 | Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index |
| Q26773191 | Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data |
| Q47548368 | Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. |
| Q44897259 | Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment |
| Q39802266 | Hepatitis C virus replication and potential targets for direct-acting agents |
| Q40527984 | Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles |
| Q27004075 | Hepatitis C virus screening and management of seroconversions in hemodialysis facilities |
| Q33600085 | Hepatitis C virus screening in patients with cancer receiving chemotherapy |
| Q33929521 | Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965 |
| Q42980230 | Hepatitis C virus seropositivity in a South African Cohort of HIV co-infected, ARV naïve patients is associated with renal insufficiency and increased mortality |
| Q42991206 | Hepatitis C virus targets the interferon-α JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes |
| Q49180756 | Hepatitis C virus testing of persons born during 1945-1965. |
| Q45355364 | Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention |
| Q45306504 | Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia. |
| Q40622385 | Hepatitis C virus treatment complicated by rheumatoid arthritis. |
| Q36172124 | Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. |
| Q39955308 | Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity |
| Q36562909 | Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance |
| Q38166700 | Hepatitis C virus: an overview for dental health care providers |
| Q51837887 | Hepatitis C worldwide and in Brazil: silent epidemic--data on disease including incidence, transmission, prevention, and treatment. |
| Q33516543 | Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers |
| Q45239017 | Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. |
| Q38635796 | Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. |
| Q50561889 | Hepatitis C: Should antiviral therapy be offered to elderly patients? |
| Q37252944 | Hepatitis C: current and future therapies |
| Q43591832 | Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre |
| Q39794346 | Hepatitis-C prevalence in an urban native-American clinic: a prospective screening study. |
| Q37157400 | Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. |
| Q37015123 | Hepatocellular carcinoma prevalence and mortality in a male state prison population |
| Q33866448 | Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations |
| Q37380420 | Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey |
| Q36858864 | High Hepatitis C Infection Rate Among Baby Boomers in an Urban Primary Care Clinic: Results from the HepTLC Initiative |
| Q40750705 | High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens |
| Q39163884 | High frequency of active HCV infection among seropositive cases in west Africa and evidence for multiple transmission pathways |
| Q43926538 | High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program |
| Q43046515 | High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack |
| Q36858890 | High-Yield Birth-Cohort Hepatitis C Virus Screening and Linkage to Care Among Underserved African Americans, Atlanta, Georgia, 2012-2013. |
| Q33691250 | Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. |
| Q36102410 | Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males |
| Q36791363 | Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children |
| Q39403806 | Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia |
| Q41562307 | Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. |
| Q38203033 | Historical epidemiology of hepatitis C virus (HCV) in selected countries. |
| Q45325255 | Historical epidemiology of hepatitis C virus in select countries—volume 4 |
| Q34280145 | Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis |
| Q37781667 | Host genetic basis for hepatitis C virus clearance: a role for blood collection centers |
| Q49688967 | How outpatient substance abuse treatment unit director activities may affect provision of community outreach services |
| Q45843799 | How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy |
| Q38887166 | Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. |
| Q42857506 | IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. |
| Q34287407 | IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population |
| Q36457789 | ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. |
| Q36509228 | Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. |
| Q34627200 | Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis |
| Q34403294 | Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay |
| Q34023364 | Identification of substance use and dependence among patients with viral hepatitis |
| Q33587555 | Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach |
| Q58095372 | Identifying barriers to treatment of HCV in the primary care setting |
| Q37629959 | Immune markers associated with host susceptibility to infection with West Nile virus |
| Q40120487 | Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. |
| Q39238840 | Impact of birth cohort screening for hepatitis C. |
| Q47785236 | Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients |
| Q42980522 | Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection |
| Q50574695 | Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. |
| Q35606675 | Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen Behavioral Model for Vulnerable Populations |
| Q35985401 | Impact of hepatitis C virus eradication on hepatocellular carcinogenesis |
| Q27487855 | Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies |
| Q37419326 | Impact of new therapeutics for hepatitis C virus infection in incarcerated populations |
| Q59418647 | Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care |
| Q44626456 | Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection |
| Q27487035 | Impaired Hepatitis C Virus (HCV)-Specific Effector CD8+ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection |
| Q42190310 | Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis |
| Q37807853 | Importance of Hepatitis Vaccination in Patients with Chronic Liver Disease |
| Q36367343 | Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis |
| Q43001380 | Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study |
| Q43850787 | Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. |
| Q36858894 | Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014. |
| Q37180035 | In the clinic. Hepatitis C. |
| Q34351108 | Incidence analyses and space-time cluster detection of hepatitis C in Fujian Province of China from 2006 to 2010. |
| Q34677310 | Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study |
| Q33939214 | Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States |
| Q35690302 | Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. |
| Q39151731 | Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. |
| Q64136945 | Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009 |
| Q50545604 | Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. |
| Q38839753 | Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study |
| Q58750606 | Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage |
| Q36299364 | Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection |
| Q33803919 | Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors |
| Q46398965 | Increasing hepatitis C knowledge among homeless adults: results of a community-based, interdisciplinary intervention |
| Q56654945 | Increasing hepatitis C screening in a large integrated health system: science and policy in concert |
| Q34777639 | Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection |
| Q51872330 | Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. |
| Q34638892 | Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases |
| Q92108145 | Infección por el virus de la hepatitis C en pacientes con enfermedad renal crónica |
| Q37074647 | Infection with hepatitis C virus among HIV-infected pregnant women in Thailand |
| Q42271360 | Infectivity of hepatitis C virus correlates with the amount of envelope protein E2: development of a new aptamer-based assay system suitable for measuring the infectious titer of HCV. |
| Q38061619 | Influence of age and gender before and after liver transplantation |
| Q59350262 | Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV |
| Q26781991 | Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes |
| Q55459912 | Injection Site Bullous Eruption and Generalized Rash Induced by Pegylated Interferon Treatment for Hepatitis C. |
| Q33833340 | Injection and non-injection drug use and infectious disease in Baltimore City: differences by race. |
| Q35784012 | Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness |
| Q88931962 | Insulin Resistance and Metabolic Syndrome: Clinical and Laboratory Associations in African Americans Without Diabetes in the Hemochromatosis and Iron Overload Screening Study |
| Q64960668 | Integrating Care for Patients With Chronic Liver Disease and Mental Health and Substance Use Disorders. |
| Q36858878 | Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014. |
| Q35697034 | Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health |
| Q27483686 | Interferon Alpha Treatment and Thyroid Dysfunction |
| Q42988825 | Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection |
| Q40961029 | Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C. |
| Q27490833 | Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection |
| Q47901783 | Involuntary treatment of psychiatric inpatients certified under the Saskatchewan Mental Health Services Act in a secure forensic psychiatric treatment center. |
| Q37883931 | Involvement of autophagy in alcoholic liver injury and hepatitis C pathogenesis |
| Q34041411 | Is chronic hepatitis C virus infection a risk factor for breast cancer? |
| Q38556915 | Is the 25-year hepatitis C marathon coming to an end to declare victory? |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q44088527 | Killing two birds with one stone: screening for chronic hepatitis C at the time of colonoscopy in the baby boomer cohort |
| Q35910776 | Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes |
| Q42271736 | Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults |
| Q33643564 | Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study |
| Q40063920 | Knowledge, attitudes and barriers regarding vaccination against hepatitis A and B in patients with chronic hepatitis C virus infection: a survey of family medicine and internal medicine physicians in the United States. |
| Q44113629 | Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings |
| Q34034846 | Lack of association between hepatitis C infection and chronic kidney disease |
| Q36950964 | Lamivudine treatment for severe acute HBV hepatitis |
| Q37626109 | Large scale screening of human sera for HCV RNA and GBV-C RNA. |
| Q34158177 | Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users |
| Q40516026 | Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors |
| Q37287281 | Lay management of chronic disease: a qualitative study of living with hepatitis C infection |
| Q39023015 | Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant |
| Q42265655 | Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study |
| Q35435112 | Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma |
| Q64936868 | Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system. |
| Q34135694 | Ligand-induced changes in hepatitis C virus NS5B polymerase structure |
| Q28081216 | Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes |
| Q30450772 | Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis |
| Q33889865 | Liver cancer mortality among male prison inmates in Texas, 1992-2003. |
| Q46821226 | Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. |
| Q40152953 | Liver disease in adolescents: A cohort study of high-risk individuals |
| Q42780223 | Liver physiology and liver diseases in the elderly |
| Q45325465 | Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry |
| Q37458352 | Liver transplantation in the ethnic minority population: challenges and prospects |
| Q40378121 | Long-Term Liver Diseases after Initiation of Antiretroviral Therapy in HIV-Infected Patients with and without HBV or HCV Coinfection |
| Q37172667 | Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up |
| Q40417472 | Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid |
| Q36769099 | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy |
| Q41013952 | Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index |
| Q43974244 | Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. |
| Q35696969 | Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs |
| Q36213687 | Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. |
| Q38433971 | Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin |
| Q36984871 | Management algorithm for genotype 1 hepatitis C virus |
| Q36995854 | Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century |
| Q34538771 | Management of Hepatitis C Antiviral Therapy Adverse Effects |
| Q37194817 | Management of chronic hepatitis C in veterans: the potential of integrated care models |
| Q36949500 | Management of hepatitis C virus infection: the basics |
| Q34298333 | Management of recurrent hepatitis C following liver transplantation |
| Q35696990 | Managing chronic hepatitis C in primary-care settings: more than antiviral therapy |
| Q27490409 | Managing chronic hepatitis C in the difficult-to-treat patient |
| Q64076810 | Manipulation of Type I Interferon Signaling by HIV and AIDS-Associated Viruses |
| Q37678082 | Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities |
| Q42981361 | Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report |
| Q42222368 | Maternal hepatitis B and hepatitis C infection and neonatal neurological outcomes. |
| Q35752296 | Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago |
| Q33651573 | Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary |
| Q38260637 | Measuring chronic liver disease mortality using an expanded cause of death definition and medical records in Connecticut, 2004. |
| Q33401841 | Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction |
| Q34143327 | Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. |
| Q39740604 | Medication-assisted treatment for substance use disorders within a national community health center research network |
| Q43571174 | Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection |
| Q37151984 | Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection |
| Q43000543 | Meta‐analysis: re‐treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy |
| Q37793952 | Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil |
| Q33744064 | Migration patterns of hepatitis C virus in China characterized for five major subtypes based on samples from 411 volunteer blood donors from 17 provinces and municipalities |
| Q33637385 | Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice |
| Q86617180 | Missed opportunities for hepatitis C testing in opioid treatment programs |
| Q37499070 | Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. |
| Q92951971 | Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago |
| Q34035703 | Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life |
| Q28548657 | Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland |
| Q92049257 | Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink? |
| Q45326463 | Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study |
| Q39895389 | Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection |
| Q35660841 | Molecular and contextual markers of hepatitis C virus and drug abuse. |
| Q42237381 | Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. |
| Q51846242 | Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009. |
| Q35200471 | Multiple Comorbid Conditions among Middle-Aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care |
| Q38126931 | Multiple infections and cancer: implications in epidemiology |
| Q39313413 | Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir |
| Q34354269 | National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States |
| Q36790704 | National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. |
| Q39224660 | National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011. |
| Q42208880 | Natural history and management of hepatitis C: does sex play a role? |
| Q93120235 | Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model |
| Q40169020 | Neighborhood Inequalities in Hepatitis C Mortality: Spatial and Temporal Patterns and Associated Factors |
| Q33652957 | Neurocognitive effects of HIV, hepatitis C, and substance use history |
| Q36404194 | Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? |
| Q36584038 | Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing. |
| Q37649337 | New markers for diagnosis and management of chronic hepatitis C virus infection |
| Q38031097 | New pharmacotherapy for hepatitis C. |
| Q36652084 | New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis |
| Q52564579 | Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines. |
| Q37030570 | News from the CDC: Translating science into HCV infection screening recommendations |
| Q26747561 | Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals |
| Q40701509 | No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening |
| Q89558079 | Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965 |
| Q45102502 | Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort |
| Q34700417 | Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis |
| Q39782827 | Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors |
| Q84704956 | Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC) |
| Q38201712 | Novel drugs in the management of difficult-to-treat hepatitis C genotypes |
| Q42977312 | Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand |
| Q64266035 | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients |
| Q36646287 | On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial |
| Q59353323 | Optimal Information Collection Policies in a Markov Decision Process Framework |
| Q38983274 | Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment |
| Q33855483 | Optimizing the dose and duration of therapy for chronic hepatitis C. |
| Q38893244 | Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review |
| Q43888512 | Outcome after liver transplantation for NASH cirrhosis |
| Q43040992 | Outcome of screening for hepatitis C virus infection based on risk factors |
| Q38272589 | Outcomes in liver transplantation: does sex matter? |
| Q41697526 | Outcomes of a hepatitis C screening protocol in at-risk adults with prior cardiac surgery |
| Q36909187 | PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation |
| Q36240463 | Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C. |
| Q57109962 | Pandemic influenza: implications for programs controlling for HIV infection, tuberculosis, and chronic viral hepatitis |
| Q33394547 | Pathobiology and treatment of hepatitis virus-related thrombocytopenia |
| Q33924602 | Patient acceptance of universal screening for hepatitis C virus infection |
| Q35138230 | Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients |
| Q35905912 | Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection |
| Q57152417 | Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients |
| Q37885222 | Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials |
| Q42988204 | Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients |
| Q42656554 | Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study |
| Q33956478 | Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response |
| Q37774238 | Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. |
| Q44563448 | Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials |
| Q35055436 | Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study |
| Q43040568 | Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites |
| Q36172195 | Performance of the Abbott RealTime HCV Genotype II RUO assay |
| Q45331913 | Persistence with hepatitis C therapy in the Department of Veterans Affairs |
| Q64948520 | Perspectivas a largo plazo: pacientes que seguirán sin tratamiento en la era de la terapia triple. |
| Q27332812 | Perspective: test and treat this silent killer |
| Q30365599 | Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents |
| Q33977230 | Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007. |
| Q33778635 | Physician nonadherence with a hepatitis C screening program |
| Q84813538 | Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection |
| Q36065593 | Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection |
| Q33644558 | Population-based surveillance for hepatitis C virus, United States, 2006-2007 |
| Q40049914 | Population-level intervention and information collection in dynamic healthcare policy. |
| Q23917138 | Postexposure Interventions to Prevent Infection With HBV, HCV, or HIV, and Tetanus in People Wounded During Bombings and Other Mass Casualty Events—United States, 2008: Recommendations of the CDC and Disaster Medicine and Public Health Preparedness |
| Q45382596 | Postmortem detection of hepatitis B, C, and human immunodeficiency virus genomes in blood samples from drug-related deaths in Denmark*. |
| Q45348539 | Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force |
| Q42993706 | Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience |
| Q37287839 | Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. |
| Q39204755 | Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy |
| Q27487539 | Predicting response to hepatitis C therapy |
| Q34409039 | Predicting the probable outcome of treatment in HCV patients |
| Q39350754 | Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models |
| Q50558655 | Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. |
| Q38160178 | Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis |
| Q37204909 | Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States |
| Q56917418 | Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus |
| Q36698904 | Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. |
| Q38755645 | Predictors of hepatitis C testing intention among African American Baby Boomers. |
| Q34001628 | Predictors of pain intensity and pain functioning in patients with the hepatitis C virus |
| Q45332298 | Predictors of response of US veterans to treatment for the hepatitis C virus |
| Q34779758 | Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection |
| Q34719654 | Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors |
| Q64060840 | Preliminary Screening Results Outside the 1945–1965 Birth Cohort: A Forgotten Population for Hepatitis C? |
| Q27481007 | Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy |
| Q33638473 | Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea |
| Q45340710 | Prevalence and association of hepatitis C virus infection with different types of lymphoma. |
| Q38984477 | Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward |
| Q37060330 | Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients |
| Q27489255 | Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil |
| Q37642596 | Prevalence and risk factors for hepatitis C and human immunodeficiency virus coinfection among children in enugu, Nigeria |
| Q35503257 | Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection |
| Q39269495 | Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades |
| Q34572367 | Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study |
| Q38323723 | Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs |
| Q51865193 | Prevalence of HCV infection among clients in community-based health settings in Hawaii, 2002-2010: assessing risk factors. |
| Q84762884 | Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use |
| Q64118358 | Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices |
| Q51541188 | Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study |
| Q39294392 | Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey |
| Q51847669 | Prevalence of hepatitis C in two inpatient psychiatry populations. |
| Q37470465 | Prevalence of hepatitis C infection in New York City, 2004 |
| Q42985162 | Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey |
| Q28583333 | Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis |
| Q37719745 | Prevalence of hepatitis C virus infection in US Hispanic/Latino adults: results from the NHANES 2007-2010 and HCHS/SOL studies |
| Q37069225 | Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States |
| Q33947985 | Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. |
| Q39893002 | Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. |
| Q36005257 | Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles |
| Q37445121 | Prevention of hepatocellular carcinoma complicating chronic hepatitis C. |
| Q33686837 | Preventive healthcare for underserved women: results of a prison survey |
| Q51852531 | Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. |
| Q37573484 | Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. |
| Q47330339 | Process of care for hepatitis C infection is linked to treatment outcome and virologic response |
| Q34329744 | Profile of alisporivir and its potential in the treatment of hepatitis C. |
| Q36407292 | Profile of lifetime methamphetamine use among homeless adults in Los Angeles |
| Q37223719 | Profound jaundice in a patient with acute hepatitis C. |
| Q33568912 | Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data |
| Q60924290 | Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? |
| Q33921088 | Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis |
| Q24676417 | Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico |
| Q36456976 | Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma |
| Q27487518 | Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon |
| Q34365319 | Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial |
| Q37385877 | Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. |
| Q44393867 | Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients |
| Q38255471 | Proteasome- and ethanol-dependent regulation of HCV-infection pathogenesis |
| Q36296243 | Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment |
| Q34743058 | Psychiatric care of the patient with hepatitis C: a review of the literature |
| Q36642912 | Psychiatric management of the hepatitis C patient. |
| Q35215510 | Psychosocial correlates of alcohol use and reduction for individuals with hepatitis C |
| Q36813466 | Public health clinic-based hepatitis C testing and linkage to care in Baltimore. |
| Q39939298 | Public health impact of antiviral therapy for hepatitis C in the United States |
| Q51778568 | Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. |
| Q35796138 | Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. |
| Q45074467 | Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin |
| Q35971578 | Quality of hepatitis C care at an urban tertiary care medical center |
| Q45354911 | Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. |
| Q37156704 | Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial |
| Q34210374 | RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. |
| Q55259186 | Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. |
| Q35990198 | Race and ethnicity in access to and outcomes of liver transplantation: a critical literature review |
| Q36988702 | Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States |
| Q36499522 | Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic |
| Q37077462 | Racial differences in hepatitis C treatment eligibility |
| Q42235045 | Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. |
| Q39140437 | Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III. |
| Q37095472 | Racial disparity in liver disease: Biological, cultural, or socioeconomic factors |
| Q35856819 | Raising awareness of viral hepatitis: National Hepatitis Testing Day, May 19. |
| Q36146807 | Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment |
| Q38074389 | Rapid diagnostic HCV antibody assays |
| Q42225777 | Rapid hepatitis C testing among persons at increased risk for infection--Wisconsin, 2012-2013. |
| Q35800747 | Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C |
| Q59360131 | Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system |
| Q35258724 | Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics |
| Q55517939 | Recent Advances in Hepatitis C: Highlights from the 2010 AASLD Meeting. |
| Q57797758 | Recombinant streptavidin fusion proteins as signal reporters in rapid test of human hepatitis C virus infection |
| Q51831518 | Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. |
| Q45351130 | Regional and global summary estimates of antibody to hepatitis C virus prevalence in detainee populations: seeing the forest and the trees? |
| Q40440166 | Regulation of HepG2 cell apoptosis by hepatitis C virus (HCV) core protein via the sirt1-p53-bax pathway |
| Q37046078 | Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus |
| Q35071918 | Relationship between hepatitis C clinical testing site and linkage to care |
| Q33905877 | Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin |
| Q50991688 | Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". |
| Q42993494 | Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. |
| Q37478964 | Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites |
| Q35752660 | Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program |
| Q36858838 | Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. |
| Q52587031 | Results of a Hepatitis C Virus Screening Program of the 1945-1965 Birth Cohort in a Large Emergency Department in New Jersey. |
| Q40317993 | Retention in buprenorphine treatment is associated with improved HCV care outcomes |
| Q37883962 | Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study |
| Q40337034 | Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay. |
| Q33731308 | Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? |
| Q37100251 | Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime |
| Q36942006 | Review article: vaccination and viral hepatitis - current status and future prospects |
| Q34062040 | Review. |
| Q37886161 | Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? |
| Q40039560 | Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics |
| Q57007148 | Risk assessment and screening for sexually transmitted infections, HIV, and hepatitis virus among long-distance truck drivers in New Mexico, 2004-2006 |
| Q36773533 | Risk factor profiles among intravenous drug using young adults: a latent class analysis (LCA) approach |
| Q33872878 | Risk factors associated with Hepatitis C among female substance users enrolled in community-based HIV prevention studies |
| Q51816433 | Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. |
| Q42228011 | Risk factors for hepatitis C infection among Vietnam era veterans versus nonveterans: results from the Chronic Hepatitis Cohort Study (CHeCS). |
| Q89724932 | Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study |
| Q51334330 | Risk factors for infection with different hepatitis C virus genotypes in southern Brazil. |
| Q33977173 | Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans |
| Q27490427 | Risk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120 908 US Veterans With Hepatitis C Virus Infection |
| Q37286554 | Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans |
| Q36208036 | Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection |
| Q36795672 | Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study |
| Q35032861 | Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis |
| Q34577683 | Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C. |
| Q83353643 | Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic |
| Q37693948 | Role of ribavirin in HCV treatment response: now and in the future |
| Q37399645 | Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment |
| Q40539146 | Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. |
| Q31019494 | Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data |
| Q37892162 | Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review |
| Q37630878 | Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist |
| Q36725027 | Sampling and recruitment in multilevel studies among marginalized urban populations: the IMPACT studies |
| Q39634561 | Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands |
| Q53516428 | Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. |
| Q35926098 | Screening for hepatitis C in average and high-risk populations of Qatar using rapid point-of-care testing |
| Q47581694 | Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007. |
| Q45401455 | Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy |
| Q33774344 | Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. |
| Q36579211 | Senior Center-Based Hepatitis C Screening in Baltimore |
| Q37395341 | Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? |
| Q33544908 | Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico |
| Q44684380 | Seropositive abdominal and thoracic donor organs are largely underutilized |
| Q36612780 | Seroprevalence and risk factors of Hepatitis B and Hepatitis C infections among pregnant women in the Asante Akim North Municipality of the Ashanti region, Ghana; a cross sectional study |
| Q34390184 | Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu |
| Q36609564 | Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley |
| Q42231565 | Seroprevalence rates of hepatitis C virus (HCV) antibody and hepatitis B virus surface antigen (HBsAG) in blood donors in a Southwestern Nigerian city |
| Q35662485 | Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. |
| Q42110866 | Serum alpha-fetoprotein level is higher in hepatitis C than hepatitis B infected chronic liver disease patients |
| Q43001446 | Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort |
| Q37613314 | Serum γ-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults |
| Q37032685 | Severe mental illness is a new risk marker for blood-borne viruses and sexually transmitted infections. |
| Q42998640 | Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys |
| Q34964129 | Sex disparities in cancer incidence by period and age. |
| Q34426531 | Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males |
| Q59349492 | Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma |
| Q36594952 | Sexual risk behavior associated with transition to injection among young non-injecting heroin users |
| Q34645642 | Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study |
| Q37111444 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients |
| Q47603693 | Should we treat acute hepatitis C? A decision and cost-effectiveness analysis |
| Q41426862 | Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin |
| Q40035445 | Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience |
| Q42775123 | Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response |
| Q41103870 | Skin rash during chronic hepatitis C therapy. |
| Q36312926 | Social networks and HCV viraemia in anti-HCV-positive rural drug users. |
| Q33395403 | Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection |
| Q36918975 | Socioeconomic status in HCV infected patients - risk and prognosis |
| Q38219424 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. |
| Q57841253 | Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting |
| Q40280603 | Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. |
| Q34624732 | Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial |
| Q57841241 | Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study |
| Q38085326 | Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection |
| Q50283110 | Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection |
| Q39824771 | Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection |
| Q51869378 | Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. |
| Q34158520 | Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia |
| Q39177479 | Spending on Hepatitis C Antivirals in the United States, 2009-2015. |
| Q48365558 | Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. |
| Q38227133 | Split-luciferase complementary assay: applications, recent developments, and future perspectives |
| Q36141258 | Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. |
| Q34747195 | Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C |
| Q40779777 | Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States |
| Q49942281 | Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs |
| Q40565281 | Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. |
| Q37435745 | Successful Integration of Hepatitis C Virus Point-of-Care Tests into the Denver Metro Health Clinic |
| Q33858467 | Successful integration of hepatitis C evaluation and treatment services with methadone maintenance |
| Q37216987 | Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program |
| Q38321799 | Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors |
| Q87798658 | Surgeon general's perspectives |
| Q55424407 | Survey of US Correctional Institutions for Routine HCV Testing. |
| Q35698198 | Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial |
| Q37274308 | Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States |
| Q34609714 | Survival rates of early-stage HCV-related liver cirrhosis patients without hepatocellular carcinoma are decreased by alcohol |
| Q47236942 | Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. |
| Q27478368 | Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets |
| Q35116027 | Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication |
| Q39673107 | Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors |
| Q36827264 | Systematic analysis of enhancer and critical cis-acting RNA elements in the protein-encoding region of the hepatitis C virus genome |
| Q36259199 | Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. |
| Q38096012 | Systematic review: Asian patients with chronic hepatitis C infection |
| Q37960561 | Telaprevir for the treatment of chronic hepatitis C infection |
| Q35270937 | Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis |
| Q37939247 | Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. |
| Q34184046 | Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. |
| Q92916687 | Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015 |
| Q53304052 | Ten years later: A single hospital experience with malignancy in HIV/AIDS |
| Q27485369 | Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates |
| Q42073639 | Texas statewide hepatitis C counseling and testing, 2000-2005 |
| Q37693859 | The Association between Female Genital Cutting and Spousal HCV Infection in Egypt |
| Q26795711 | The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis |
| Q27485895 | The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors |
| Q59356988 | The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial |
| Q36446133 | The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States |
| Q43011629 | The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. |
| Q33621649 | The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C. |
| Q27486939 | The Role of Obstetrician/Gynecologists in the Management of Hepatitis C Virus Infection |
| Q26777560 | The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis |
| Q36975130 | The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco |
| Q34575747 | The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation |
| Q36035140 | The association of perceived stress and verbal memory is greater in HIV-infected versus HIV-uninfected women |
| Q40168920 | The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics |
| Q58441411 | The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey |
| Q37144257 | The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. |
| Q45357120 | The burden of untreated hepatitis C virus infection: a US patients' perspective |
| Q21559628 | The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting |
| Q35168083 | The changing burden of hepatitis C virus infection in the United States: model-based predictions. |
| Q26795559 | The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment |
| Q40231197 | The continuum of hepatitis C testing and care. |
| Q42242240 | The contribution of viral hepatitis to the burden of chronic liver disease in the United States |
| Q33834958 | The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings |
| Q35696958 | The costs and impacts of testing for hepatitis C virus antibody in public STD clinics |
| Q28662145 | The current hepatitis C virus prevalence in China may have resulted mainly from an officially encouraged plasma campaign in the 1990s: a coalescence inference with genetic sequences |
| Q41843629 | The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes |
| Q39904505 | The disposition of hepatitis C antibody-positive patients in an urban hospital |
| Q64061966 | The distribution and socioeconomic burden of Hepatitis C virus in South Australia: a cross-sectional study 2010-2016 |
| Q43036906 | The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. |
| Q42545300 | The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection |
| Q30831694 | The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial |
| Q36746575 | The effects of HCV infection and management on health-related quality of life |
| Q36934243 | The epidemiology of hepatitis C in a Canadian Indigenous population |
| Q36892181 | The epidemiology of hepatitis C infection in the United States |
| Q26784519 | The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis |
| Q47556282 | The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses |
| Q55130317 | The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. |
| Q44280003 | The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance |
| Q42978363 | The expression kinetics of CD137 in chronic hepatitis C patients treated with pegylated-interferon and ribavirin |
| Q36558091 | The feasibility and acceptability of a multimedia hepatitis C prevention program for Hispanic HIV-infected persons |
| Q63246355 | The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment |
| Q39878799 | The healthcare burden imposed by liver disease in aging Baby Boomers |
| Q35927970 | The high comorbidity burden of the hepatitis C virus infected population in the United States |
| Q35945429 | The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort |
| Q51891686 | The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. |
| Q38052034 | The impact of ethnicity on hepatitis C virus treatment decisions and outcomes |
| Q40135936 | The impact of hepatitis C virus infection on 90-day outcomes following major orthopaedic surgery: a propensity-matched analysis. |
| Q36185899 | The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan |
| Q42988978 | The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States |
| Q34552460 | The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients |
| Q39883472 | The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. |
| Q37663322 | The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study |
| Q92669615 | The long-term horizon: Patients who will remain untreated in the era of triple therapy |
| Q37588861 | The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. |
| Q37282591 | The natural history of recurrent hepatitis C and what influences this |
| Q37455611 | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices |
| Q38915259 | The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C |
| Q39589157 | The performance of process measures in hepatitis C. |
| Q42993391 | The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations |
| Q38147375 | The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus |
| Q37191611 | The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). |
| Q37332151 | The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections |
| Q30671794 | The prevalence of harmful and hazardous alcohol consumption in older U.S. adults: data from the 2005-2008 National Health and Nutrition Examination Survey (NHANES). |
| Q38204657 | The rapid evolution of treatment strategies for hepatitis C. |
| Q46345046 | The role of attachment style and depression in patients with hepatitis C. |
| Q37397265 | The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice |
| Q89859426 | The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs |
| Q92411348 | The role of tacstd-2 level in hepatitis C patients (controlled clinical research) |
| Q37825956 | The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients |
| Q38634221 | The safety of daclatasvir for the treatment of hepatitis C. |
| Q37095874 | The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models |
| Q46623464 | The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. |
| Q34533359 | The swinging thyroid in hepatitis C infection and interferon therapy |
| Q33837518 | The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis |
| Q33977325 | Three years after legalization of nonprescription pharmacy syringe sales in California: where are we now? |
| Q33440130 | Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection |
| Q26827517 | Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective |
| Q33909535 | Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study |
| Q33690260 | Tickling the TLR7 to cure viral hepatitis |
| Q80996632 | Time for renewed commitment to viral hepatitis prevention |
| Q35585471 | Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland |
| Q37469924 | Toll-like receptors as targets in chronic liver diseases |
| Q34484872 | Toward a more accurate estimate of the prevalence of hepatitis C in the United States |
| Q37738643 | Training for a career in hepatology: which path to take? |
| Q91656059 | Training the next generation of hepatologist: What will they need to know? |
| Q34524584 | Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline |
| Q43041567 | Transmission of hepatitis C virus among spouses in Cameroon and the Central African Republic |
| Q36185545 | Transmission of hepatitis C virus infection through tattooing and piercing: a critical review |
| Q47402203 | Transporter expression in non-cancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. |
| Q47595176 | Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments |
| Q38016958 | Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents |
| Q28552691 | Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C |
| Q81154169 | Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study |
| Q30224806 | Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection |
| Q59360780 | Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice |
| Q38581478 | Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. |
| Q37855530 | Treatment of acute HCV infection |
| Q37693926 | Treatment of chronic hepatitis C in elderly patients |
| Q38177972 | Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles |
| Q38741769 | Treatment of dyslipidemia with statins by primary care providers in Veterans with and without chronic Hepatitis C. |
| Q40973051 | Treatment of hepatitis C in patients with HIV. |
| Q38123948 | Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. |
| Q41923073 | Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population |
| Q41806895 | Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection |
| Q33916357 | Treatment options for HCV nonresponders and relapse patients |
| Q27489011 | Treatment responses in Asians and Caucasians with chronic hepatitis C infection |
| Q50568858 | Treatment strategy for hepatitis C after liver transplantation. |
| Q37886279 | Trends and projections of hepatitis C virus epidemiology in Latin America. |
| Q93101282 | Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis |
| Q34021608 | Trends in waiting list registration for liver transplantation for viral hepatitis in the United States |
| Q36082433 | Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort |
| Q34587019 | U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients |
| Q33947453 | Uncommon hepatitis B virus and/or hepatitis C virus occult infection in HIV-positive patients with abnormal level of hepatic enzyme |
| Q42635260 | Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use. |
| Q33607231 | Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals |
| Q42208893 | Unmet health care needs and hepatitis C infection among persons who inject drugs in Denver and Seattle, 2009. |
| Q35906047 | Update on Hepatitis C Virus and HIV Coinfection |
| Q94338905 | Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif.With commentary by:Fred Poordad, MDCedars-Sinai Medical CenterLos Angel |
| Q35713666 | Upper limits of normal for alanine aminotransferase activity in the United States population |
| Q37785472 | Use of Statins in Patients with Chronic Hepatitis C |
| Q35640461 | Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C |
| Q31121311 | Use of national health interview data to measure the burden of disease and injuries |
| Q35781318 | Use of parenteral caffeinum natrio-benzoicum: an underestimated risk factor for HCV transmission in China |
| Q36555228 | Use of the AST to platelet ratio index in HCV/HIV co-infected patients |
| Q38265121 | Utility of evaluating HCV in an uninsured population |
| Q46076105 | Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US. |
| Q38688624 | Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change |
| Q35543019 | Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined |
| Q44645659 | Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies |
| Q34708289 | Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database |
| Q37326067 | Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection |
| Q28248241 | Vertical hepatitis C virus transmission: Main questions and answers |
| Q34263352 | Vertical transmission of hepatitis C virus: Current knowledge and perspectives |
| Q24681387 | Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response |
| Q35916158 | Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma |
| Q37463420 | Viral hepatitis and injection drug use in Appalachian Kentucky: a survey of rural health department clients |
| Q37980037 | Viral hepatitis in the elderly |
| Q38064527 | Viral infections and their management in patients with chronic lymphocytic leukemia. |
| Q27027087 | Viral infections during pregnancy |
| Q36812745 | Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer |
| Q27666298 | Visualizing ATP-Dependent RNA Translocation by the NS3 Helicase from HCV |
| Q42991908 | Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011. |
| Q40519915 | Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder |
| Q35080930 | WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients |
| Q27490841 | Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment |
| Q41745939 | What are the management issues for hepatitis C in dialysis patients?: management of hepatitis C infection in kidney transplant candidates |
| Q38569681 | What does the pharmacological future of treating chronic hepatitis C look like? |
| Q45903741 | What's new in the other general journals. |
| Q38793776 | Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature |
| Q45362932 | Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? |
Search more.